{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:34:03Z","timestamp":1780446843792,"version":"3.54.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2002,3]]},"DOI":"10.1016\/s0002-9149(02)02229-4","type":"journal-article","created":{"date-parts":[[2002,10,11]],"date-time":"2002-10-11T01:18:58Z","timestamp":1034299138000},"page":"50-57","source":"Crossref","is-referenced-by-count":31,"special_numbering":"S1","title":["Managing dyslipidemia in the high-risk patient"],"prefix":"10.1016","volume":"89","author":[{"given":"Evan A","family":"Stein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S0002-9149(02)02229-4_BIB1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB2","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB3","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB4","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on cholesterol events","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB5","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB6","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0002-8703(00)90033-4","article-title":"Statins","volume":"139","author":"Blumenthal","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB8","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1001\/archinte.158.18.1977","article-title":"Maximizing the cost-effectiveness of lipid-lowering therapy","volume":"158","author":"Jacobson","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB9","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB10","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1001\/jama.1993.03500230097036","article-title":"Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)","volume":"269","year":"1993","journal-title":"JAMA"},{"issue":"suppl 1","key":"10.1016\/S0002-9149(02)02229-4_BIB11","first-page":"S57","article-title":"Management of dyslipidemia in adults with diabetes","volume":"23","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB12","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1053\/euhj.1998.1243","article-title":"Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention","volume":"19","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB13","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/archinte.160.4.459","article-title":"The Lipid Treatment Assessment Project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein goals","volume":"160","author":"Pearson","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB14","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1053\/euhj.2001.2610","article-title":"Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme","volume":"22","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0002-9149(97)00298-1","article-title":"The rule of 5 and the rule of 7 in lipid-lowering by statin drugs","volume":"80","author":"Roberts","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0002-9343(01)00799-9","article-title":"Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins","volume":"111","author":"Andrews","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB17","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJM199908123410707","article-title":"Drug treatment of lipid disorders","volume":"341","author":"Knopp","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB18","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1001\/archinte.159.16.1893","article-title":"Colesevelam hydrochloride (cholestagel)","volume":"159","author":"Davidson","year":"1999","journal-title":"Arch Intern Med"},{"issue":"suppl 12A","key":"10.1016\/S0002-9149(02)02229-4_BIB19","doi-asserted-by":"crossref","first-page":"24U","DOI":"10.1016\/S0002-9149(98)00847-9","article-title":"Clinical profiles of plain versus sustained-release niacin (Niaspan) and the physiologic rationale for nighttime dosing","volume":"82","author":"Knopp","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB20","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB21","first-page":"326A","article-title":"New combination niacin\/statin formulation shows pronounced effects on major lipoproteins and is well tolerated","volume":"35","author":"Kashyap","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB22","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1161\/01.CIR.103.8.1177","article-title":"Stanol\/sterol ester-containing foods and blood cholesterol levels. A statement for healthcare professionals from the Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association","volume":"103","author":"Lichtenstein","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2796.1998.00294.x","article-title":"Compliance with and efficacy of treatment with pravastatin and cholestyramine","volume":"243","author":"Eriksson","year":"1998","journal-title":"J Intern Med"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB24","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0021-9150(01)00437-3","article-title":"Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively","volume":"158","author":"Hunninghake","year":"2001","journal-title":"Atherosclerosis"},{"issue":"suppl 12A","key":"10.1016\/S0002-9149(02)02229-4_BIB25","doi-asserted-by":"crossref","first-page":"82U","DOI":"10.1016\/S0002-9149(98)00955-2","article-title":"Treatment of hyperlipidemia with combined niacin-statin regimens","volume":"82","author":"Guyton","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0002-9149(00)00976-0","article-title":"Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy","volume":"86","author":"Blair","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB27","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0002-9149(99)00656-6","article-title":"Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Hokuriku NK-104 Study Group","volume":"85","author":"Kajinami","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB28","first-page":"p53","author":"Teramoto","year":"2000","journal-title":"Clinical evaluation of NK-104 (itavastatin) in long-term treatment of patients with hyperlipidemia"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB29","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0002-9149(01)01727-1","article-title":"Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia","volume":"88","author":"Olsson","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB30","first-page":"292A","article-title":"ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia","volume":"37","author":"Stein","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB31","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0002-9149(01)02226-3","article-title":"Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin vs atorvastatin in patients with type IIa or IIb hypercholesterolemia","volume":"89","author":"Davidson","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB32","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00043798-200112000-00008","article-title":"Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolemic patients","volume":"8","author":"Paoletti","year":"2001","journal-title":"J Cardiovasc Risk"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB33","author":"Stein","year":"2001","journal-title":"Effect of rosuvastatin on high density lipoprotein cholesterol and apolipoprotein AI in patients with heterozygous familial hypercholesterolemia [abstract]"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB34","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1152\/ajplegacy.1966.210.5.1142","article-title":"Intestinal bile salt transport","volume":"210","author":"Lack","year":"1966","journal-title":"Am J Physiol"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB35","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S0022-2275(20)39869-2","article-title":"Inhibition of ileal sodium-dependent bile acid transport by 2164U90","volume":"36","author":"Root","year":"1995","journal-title":"J Lipid Res"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB36","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/01.ATV.18.8.1304","article-title":"Inhibition of ileal Na+\/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits","volume":"18","author":"Higaki","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB37","author":"Stein","year":"2001","journal-title":"Intestinal bile acid transporter (IBAT) inhibition: results of a 4 week pilot study of 264W94\u2217, a novel IBAT inhibitor in hypercholesterolemia [abstract]"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0021-9150(00)80603-6","article-title":"Low-density-lipoprotein cholesterol reduction by SCH 58235 (ezetimibe), a novel inhibitor of intestinal cholesterol absorption in 243 hypercholesteremic subjects","volume":"151","author":"Bays","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0021-9150(00)80612-7","article-title":"Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin","volume":"151","author":"Kosoglou","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/S0002-9149(02)02229-4_BIB40","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/0021-9681(72)90178-6","article-title":"Multiple contributors to coronary risk implications for screening and prevention","volume":"25","author":"Gordon","year":"1972","journal-title":"J Chronic Dis"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914902022294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914902022294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T04:25:37Z","timestamp":1620188737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914902022294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,3]]}},"alternative-id":["S0002914902022294"],"URL":"https:\/\/doi.org\/10.1016\/s0002-9149(02)02229-4","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2002,3]]}}}